Hosted by the C-Path team, you can view this recorded webinar to learn more about the Critical Path for Rare Neurodegenerative Diseases public-private partnership.
This webinar and patient-focused roundtable will deliver an enhanced understanding of:
- The CP-RND strategic plan, its stakeholder groups and program deliverables
- The envisioned impact of CP-RND on medical product development in rare neurodegenerative diseases
- Perspectives from patients, regulators and the industry on the public-private partnership and the rare neurodegenerative disease community
Speakers and panelists included:
 |
 |
 |
| Ronald J. Bartek Co-founder/President, Friedreich’s Ataxia Research Alliance |
Lauren Boak, PhD Lifecycle Leader, GPS NSRD, Roche |
Michelle Campbell, PhD Associate Director, Stakeholder Engagement and Clinical Outcomes, U.S. Food and Drug Administration |
 |
 |
 |
| Jacqueline Corrigan-Curay, JD, MD Principal Deputy Center Director, Center for Drug Evaluation and Research, U.S. Food and Drug Administration |
Philip Green ALS Patient Advocate |
Collin Hovinga, PharmD, MS, FCCP Vice President of the Rare and Orphan Disease Programs, Critical Path Institute |
 |
 |
 |
| Walter Koroshetz, MD Director, National Institute of Neurological Disorders and Stroke |
Terina N. Martinez, PhD Executive Director, Critical Path for Rare Neurodegenerative Diseases, Critical Path Institute |
Klaus Romero, MD, MS, FCCP Chief Science Officer; Executive Director of Clinical Pharmacology, Critical Path Institute |
 |
||
| Celia Witten, MD, PhD Deputy Director, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration |
